The Prediction of Preeclampsia/Toxemia in Twin Pregnancy
- Conditions
- Preeclampsia/Toxemia
- Registration Number
- NCT01255202
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
The purpose of this study is to finout whetere uterinae artery flow , PP13 and endogolin levels in the serum and kongo red in the urine can predict preeclamsia toxemia in twin pregnancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- a women with a vaiable twin pregnany
Exclusion Criteria
- women with thrombophilya
- women terated with anticoagolant
- women with vascular disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link endoglin and PP13 to preeclampsia pathogenesis in twin pregnancies?
How do uterine artery Doppler indices compare to sFlt-1/PlGF ratios in predicting preeclampsia in twins?
Are PP13 and endoglin serum biomarkers validated for early preeclampsia detection in multifetal gestations?
What adverse maternal/fetal outcomes correlate with kongored urinary excretion in twin pregnancies?
How does TGF-β signaling inhibition via endoglin modulation compare to antihypertensive therapies in preeclampsia prevention?
Trial Locations
- Locations (1)
Assaf Harofe Medical Center
🇮🇱Zrifin, Israel
Assaf Harofe Medical Center🇮🇱Zrifin, IsraelRan Svirsky, MDPrincipal Investigator